AXSOME THERAPEUTICS, INC. Cash and Cash Equivalents
AXSOME THERAPEUTICS, INC. (AXSM) had Cash and Cash Equivalents of $319.85 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash and Cash Equivalent
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-10
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $319.85M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $305.11M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $322.93M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $325.27M.
| Period end | Cash and Cash Equivalents, at Carrying Value | Cash and Cash Equivalents, at Carrying Value as first filed |
|---|---|---|
| 2026-06-30 | $319.85M 10-Q · filed 2026-08-10 | |
| 2026-03-31 | $305.11M 10-Q · filed 2026-05-04 | |
| 2025-12-31 | $322.93M 10-Q · filed 2026-08-10 | |
| 2025-09-30 | $325.27M 10-Q · filed 2025-11-03 | |
| 2025-06-30 | $303.02M 10-Q · filed 2025-08-04 | |
| 2025-03-31 | $300.91M 10-Q · filed 2025-05-05 | |
| 2024-12-31 | $315.35M 10-K · filed 2026-02-23 | |
| 2024-09-30 | $327.34M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $315.66M 10-Q · filed 2024-08-05 | |
| 2024-03-31 | $331.44M 10-Q · filed 2024-05-06 | |
| 2023-12-31 | $386.19M 10-K · filed 2025-02-18 | |
| 2023-09-30 | $416.56M 10-Q · filed 2023-11-06 | |
| 2023-06-30 | $437.11M 10-Q · filed 2023-08-07 | |
| 2023-03-31 | $246.51M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $200.84M 10-K · filed 2024-02-23 | $200.84M 10-K · filed 2023-02-28 |
| 2022-09-30 | $227.52M 10-Q · filed 2022-11-07 | |
| 2022-06-30 | $73.39M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $84.71M 10-Q · filed 2022-05-02 | |
| 2021-12-31 | $86.47M 10-K · filed 2023-02-28 | |
| 2021-09-30 | $114.62M 10-Q · filed 2021-11-08 | |
| 2021-06-30 | $141.22M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $164.66M 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $183.88M 10-K · filed 2022-03-01 | |
| 2019-12-31 | $219.97M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |